Table 1 Baseline characteristics of 31 patients in CB (Clinical Benefit) and NCB (no- Clinical Benefit) group
Characteristic | Total (n = 31) | CB (n = 10) | NCB (n = 21) |
|---|---|---|---|
Age | |||
Median age, year(range) | 32 (19–74) | 31 (20–66) | 32 (19–74) |
Sex n. (%) | |||
Male | 25 (80.6) | 9 (90.0) | 16 (76.2) |
Female | 6 (19.4) | 1 (10.0) | 5 (23.8) |
Staging n. (%) | |||
I | NA | NA | NA |
II | 6 (19.3) | 1 (10.0) | 5 (23.8) |
III | 11 (35.5) | 3 (30.0) | 8 (38.1) |
IV | 14 (45.2) | 6 (60.0) | 8 (38.1) |
IPS | |||
< 3 | 16 (51.6) | 7 (70.0) | 14 (66.7) |
≥ 3 | 15 (48.4) | 3 (30.0) | 7 (33.3) |
Histology n. (%) | |||
Nodular sclerosis | 16 (51.6) | 6 (60.0) | 10 (47.6) |
Mixed cellularity | 12 (38.7) | 3 (30.0) | 9 (42.9) |
Lymphocyte rich | 3 (9.7) | 1 (10.0) | 2 (9.5) |
Lymphocyte depletion | NA | NA | NA |
B symptoms | 19 (61.3) | 4 (40.0) | 15 (71.4) |
EBV | 13 (41.9) | 4 (40.0) | 9 (42.9) |
HBV | 6 (19.4) | 2 (20.0) | 4 (19.0) |
Bulky disease | 6 (19.4) | 3 (30.0) | 3 (14.2) |